Targeting Surface Nucleolin Induces Autophagy-Dependent Cell Death in Pancreatic Cancer Via AMPK Activation

Cheng Xu,Yunfei Wang,Qiu Tu,Zhiye Zhang,Mengrou Chen,James Mwangi,Yaxiong Li,Yang Jin,Xudong Zhao,Ren Lai
DOI: https://doi.org/10.1038/s41388-018-0556-x
IF: 8.756
2018-01-01
Oncogene
Abstract:Pancreatic cancer remains one of the deadliest human cancers despite current advances in conventional therapeutics including surgery and adjuvant therapies. Here, we showed that LZ1, a peptide derived from a snake venom cathelicidin, significantly inhibited growth of pancreatic cancer cells by inducing autophagy-dependent cell death both in vitro and in vivo. The LZ1-induced cell death was blocked by pharmacological or genetic inhibition of autophagy. In orthotopic model of pancreatic cancer, systemic administration of LZ1 (1–4 mg/kg) exhibited remarkable antitumor efficacy, significantly prolonged mice survival, and showed negligible adverse effects by comparison with gemcitabine (20 mg/kg). Mechanistic studies revealed that LZ1 acts through binding to nucleolin, whose expression on cell surface is frequently increased in pancreatic cancer cells. LZ1 binding triggers degradation of surface-expressed nucleolin. This leads to activation of 5′-AMP kinase which results in suppression of mTORC1 activity and induction of autophagic flux. These data suggest that LZ1, targeting nucleolin–AMPK–autophagy axis, is a promising lead for the development of therapeutic agents against pancreatic cancer.
What problem does this paper attempt to address?